AbClon is at the forefront of innovative biopharmaceutical technologies, particularly in the realm of cancer treatment. The company has developed a proprietary CAR-T platform, which utilizes genetically engineered T-cells to target and eliminate cancer cells. This personalized immunotherapy approach has shown remarkable efficacy, especially in treating hematologic malignancies. AbClon’s CAR-T therapy, exemplified by its AT101 product, specifically targets the CD19 protein, demonstrating superior anti-cancer effects compared to existing therapies. The company is also advancing its zCAR-T technology, which offers a modular approach to CAR-T treatment, allowing for adjustable immune responses and the potential to target a broader range of cancers, including solid tumors.

In addition to its CAR-T platform, AbClon has developed the NEST (Novel Epitope Screening Technology) platform, which enables the discovery of antibodies that target unique sites on disease proteins. This technology facilitates the creation of novel therapeutic antibodies with distinct mechanisms of action, enhancing treatment options beyond conventional antibody therapies. Furthermore, the AffiMab platform allows for the agile development of bispecific antibodies that can simultaneously target two disease proteins, maximizing therapeutic efficacy in challenging cases. Together, these platforms position AbClon as a leader in the development of next-generation cancer therapies, with a robust pipeline aimed at addressing unmet medical needs in oncology.

South Korea

AbClon was founded in 2010 by a consortium of Korean and Swedish experts in antibody development. Our mission is to cure once incurable diseases such as cancer.

AbClon

Company Details